SCHEDULE: Frost Increases Stake in Cocrystal Pharma

Phillip Frost, M.D. and Frost Gamma Investments Trust have amended their Schedule 13D filing to report an increase in beneficial ownership of Cocrystal Pharma, Inc. common stock.

Summary

• Phillip Frost, M.D. and Frost Gamma Investments Trust (collectively, the 'Reporting Persons') have filed an amendment to their Schedule 13D, reporting changes in beneficial ownership of Cocrystal Pharma, Inc. common stock.
• The filing indicates that as of August 3, 2026, Dr. Frost beneficially owns 2,784,719 shares, representing 13.9% of the outstanding shares. This includes shares held directly, through Frost Gamma Investments Trust, and shares issuable upon exercise of options and warrants within 60 days.
• Frost Gamma Investments Trust beneficially owns 2,712,977 shares, representing 13.5% of the outstanding shares, including shares held directly and warrants exercisable within 60 days.
• The Reporting Persons acquired 75,000 shares on August 3, 2026, at $0.9412 per share and an additional 10,000 shares on August 5, 2026, at $0.9816 per share.
• The shares were purchased for investment purposes.
• The beneficial ownership percentages are calculated based on 19,263,200 shares outstanding as of August 3, 2026, plus exercisable options and warrants.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, primarily due to the disclosure of increased beneficial ownership which could signal increased influence or potential future actions, but without immediate positive or negative operational news.

Positives

• The increase in beneficial ownership by a significant stakeholder like Dr. Frost could be interpreted as a sign of confidence in the company's long-term prospects.
• The acquisition of additional shares for investment purposes suggests a belief in the company's value.

Negatives

• The filing does not contain any operational or financial performance updates, making it difficult to assess the company's current health.
• The increase in ownership by a single entity could potentially lead to concentrated control, which may be viewed negatively by some investors.

Risks

• The filing does not explicitly mention any new risks or changes to existing risk factors.
• Potential for increased influence by Dr. Frost on corporate strategy and decision-making, which could align with or diverge from other shareholders' interests.

Future Outlook

The filing does not contain any forward-looking statements or specific guidance regarding the company's future performance. The purchases are stated to be for investment purposes.

Management Comments

• Dr. Frost disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.

Industry Context

StockSavvy.ai notes that Schedule 13D filings typically indicate a significant change in beneficial ownership, often signaling a shift in investor strategy or potential activism. For a biotechnology company like Cocrystal Pharma, such filings can precede significant corporate actions or reflect a strategic re-evaluation by major shareholders.

Stakeholder Impact

• Shareholders: May observe increased influence of Dr. Frost on corporate strategy, potentially leading to changes in company direction.
• Management: May face increased scrutiny or influence from a significant beneficial owner.
• Creditors/Suppliers: No direct impact indicated by this filing.

Next Steps

• Monitor future filings from Dr. Frost and Frost Gamma Investments Trust for any further changes in beneficial ownership or disclosed intentions.
• Observe Cocrystal Pharma's strategic decisions and performance for potential impacts related to the increased stake.

Key Dates

Recommendation

The filing indicates an increase in beneficial ownership for investment purposes by a significant stakeholder. However, it lacks operational or financial updates that would justify a buy or sell recommendation. Therefore, a 'hold' stance is appropriate pending further information on the company's performance and the stakeholder's intentions.

Keywords

Cocrystal Pharma, Schedule 13D, Beneficial Ownership, Phillip Frost, Frost Gamma Investments Trust, Investment, Stock Acquisition